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BACKGROUND A thorough understanding of the patient’s genotype
and their functional response to a medication is necessary for
improving event free survival. Several outcome studies support this
view particularly if the patient is to be started on clopidogrel due to
the prevalence of clopidogrel resistance. Such guided therapy has
reduced the incidence of Major Adverse Cardiac Events (MACE) after
stent implantation.
METHODS Between August 2013 and August 2014, 200 patients with
coronary artery disease undergoing percutaneous coronary inter-
vention (PCI) were prescribed any one of the anti-
plateletmedications such as clopidogrel, prasugrel or ticagrelor and
offered testing to detect CYP2C19 gene mutations along with a
platelet reactivity assay (PRA). Intended outcome was modiﬁcation
of anti-platelet therapy deﬁned as either dose escalation of clopi-
dogrel or replacement of clopidogrel with prasugrel or ticagrelor for
the patients in clopidogrel arm, and replacement of ticagrelor or
prasugrel with clopidogrel if those patientswere non-carrier of
mutant genes and also if they demonstrated bleeding tendenciesin
the ticagrelor and prasugrel arms.
RESULTS Results obtained with the genotype assay from 200 pa-
tients showed 19.5% (n ¼ 39) of patients had normal function of the
CYP2C19 .The intermediate metabolizers formed (47%, n¼ 94) with
regards to clopidogrel metabolism. Ultra-rapid metabolizers (2.5%,
n ¼ 5), rapid metabolizers (14.5%, n ¼ 29), and poor metabolizers
(16.5%, n ¼ 33) made up the rest. Our results suggest that up to
80% the patients could beneﬁt from clopidogrel potentially using
the PRA to guide optimal dosage. VASP assay showed good corre-
lation of platelet reactivity with the genotype in patients on clopi-
dogrel Patients responding well to any of the three APTs are
expected to have a PRI below 50%. Patients responded well pre-
scribed dose of clopidogrel with a mean PRI value of 20.6% for
patients with normal genotype and 23.8% for patients with
increased metabolism genotype.Poor metabolizer showed inade-
quate response in the function test with the mean PRI value of
67%. Patients with intermediate met and were on clopidogrel (n ¼
30) varied greatly in their response to clopidogrel ranging from
4.5% to 84.6% on the PRI, PRA was valuable in determining which
of these patients could be maintained on clclopidogrel versus those
with PRI >50 needing a change in drug or dosage.
CONCLUSIONS Clopidogrel resistance was observed to be 16.5% in
our study population. PRA was useful in monitoring the efﬁcacy of
thienopyridines. By having this test, one can be safely maintained
on clopidogrel in non-carriers, or with increased dose of clopidogrel
in intermediate metabolizers or with newer drugs such as ticagrelor
or prasugrel in poor metabolizers. Patients on ticagrelor and pra-
sugrel identiﬁed as non-carriers of gene mutationsfor clopidogrel
metabolism could be offered clopidogrel resulting in economic
beneﬁts to the patients. Patients at high risk of bleeding were also
identiﬁed by the PRA.
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BACKGROUND Disruption of dual antiplatelet therapy (DAPT) for
either bleeding or due to patient non-adherence is associated with
increased adverse events. Previous studies have also varying rates of
medication adherence according to patient age. The impact of age on
DAPT disruption in PCI patients has not been examined in detail.
METHODS The PARIS registry was a multicenter, prospective obser-
vational study of patients who had successful percutaneous coronary
intervention (PCI) with stents. We compared the incidence of
disruption by cause in the three different age groups (50, 51-70, and
>70 years old).
RESULTS Disruption for bleeding progressively increased with age
whereas disruption due to patient non-adherence decreased with age.
These patterns were consistent among male and female patients.
CONCLUSIONS In this real world PCI registry, older patients had
increased incidence of disruption due to bleeding whereas younger
patients had the highest rate of disruption due to patient non-
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